US 11,446,400 B2 · Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Abstract

The present invention provides methods of monitoring and measuring tumor-associated free PSA (“fPSA”) with antibody polypeptides as an indication of androgen receptor signaling. In a particular embodiment, the methods may be used to assess the efficacy of anti-androgen and/or general anti-cancer treatments. The present invention also provides various methods and compositions relating to antibodies that are specific for tumor-associated or intratumoral fPSA. For example, the present invention provides compositions, including pharmaceutical compositions, comprising anti-fPSA antibodies, or fragments or characteristic portions thereof. The present invention further provides various therapeutic and/or diagnostic methods of using anti-fPSA antibodies and/or compositions.

Claims8

Dependent claims

A method of monitoring response to a prostate cancer treatment to a subject with a prostate tumor, the method comprising:

administering radiolabeled 5A10 antibody to a subject who has received the prostate cancer treatment;
and
imaging the administered radiolabeled 5A10 antibody in situ in the subject so that a first post-treatment level of fPSA in the prostate tumor or tissue of the subject is determined;
and comparing the first post-treatment level of fPSA in the tumor or tissue with a pre-treatment level of fPSA in the tumor or tissue of the subject, wherein a decrease in the first post-treatment level of fPSA when compared to the pre-treatment level of fPSA is indicative that the treatment is effective.

1 more element

Dependencies are inferred from the claim text.

Facts

Application

16/430,041Filed 3 Jun 2019 · continuation

Priority

25 Oct 2011

Published

US 2019/0381200 A119 Dec 2019

Granted

20 Sep 2022

Term ends

Not estimatedThe source records don’t support an estimate.

Classification14 codes

A61K 51/1018
Antibodies or immunoglobulins; Fragments thereof , the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised…
A61B 5/4381
For evaluating the male reproductive system: prostate evaluation or disorder diagnosis
A61B 5/4833
Other medical applications: assessment of subject's compliance to treatment
A61K 51/1072
Against animal or human tumor cells or tumor cell determinants: the tumor cell being from the reproductive system, e.g. ovaria, uterus, testes or…

Family

Application61/551,195Us provisional application · filed 25 Oct 2011

PCT/US2012/061982Parent of this continuation · filed 25 Oct 2012

US 2019/0381200 A1Pre-grant publication · published 19 Dec 2019

Application14/353,989Parent of this continuation

US 2014/0308204 A1Published application

US 11,446,400 B2This patent

From the US filing history. Foreign family members aren’t listed.

Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Life of this patent

Free PSA antibodies as diagnostics, prognostics and therapeutics for prostate cancer

Life of this patent

Abstract

Claims8